BETA: Please send your feedback!
Corcept Therapeutics
CORT:NAS
Pharmaceuticals: Other
—
SMALL cap
(—)
—
since start of 2022
—
About
Pharmaceuticals: Other
Founded 1998
Corcept Therapeutics, Inc. engages in the development of drugs for the treatment of severe psychiatric, neurological, and metabolic disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.
website
Headquarters
Executives
| Name | Title | Gender |
| Joseph K. Belanoff, MD | President, Chief Executive Officer, Director & MD | Male |
| Robert S. Fishman, MD | Chief Medical Officer | Male |
| Susan P. Rinne | Vice President-Corporate Regulatory Affairs | Female |
| David B. Singer, MBA | Founder | Male |
| James N. Wilson, MBA | Chairman | Male |
| Gary Charles Robb | Secretary & Chief Financial Officer | Male |
Mindful Investing Summary
Corcept Therapeutics - Competitors and Related Companies
How Corcept Therapeutics stacks up to its peers in the Pharmaceuticals: Other industry or with competing business segments.
Corcept Therapeutics
CORT:NAS
Pharmaceuticals: Other
—
SMALL cap
(—)
—
since start of 2022
—
Impax Laboratories
IPXL:NAS
Pharmaceuticals: Generic
—
SMALL cap
(—)
—
since start of 2022
—
Catalyst Biosciences
CBIO:NAS
Biotechnology
—
MICRO cap
(—)
—
since start of 2022
—
Eli Lilly
LLY:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2022
—
Johnson & Johnson
JNJ:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2022
—
Novartis
NOVN-CH:SWX
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2022
—